not represent a determination by the Board that the proposal meets or is likely to meet the standards of the BHC Act.

Any comments or requests for hearing should be submitted in writing and received by William W. Wiles, Secretary, Board of Governors of the Federal Reserve System, Washington, D.C. 20551, not later than October 27, 1995. Any request for a hearing on this proposal must, as required by section 262.3(e) of the Board's Rules of Procedure (12 CFR 262.3(e)), be accompanied by a statement of the reasons why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal. The notice may be inspected at the offices of the Board of Governors or the Federal Reserve Bank of Atlanta.

Board of Governors of the Federal Reserve System, October 11, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–25673 Filed 10–13–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Senior Executive Service; Performance Review Board Members

Title 5, U.S. Code, Section 4314(c)(4) of the Civil Service Reform Act of 1978, Public Law 95–454, requires that the appointment of Performance Review Board members be published in the Federal Register.

Dated: September 29, 1995.

Eugene Kinlow,

Acting Assistant Secretary for Personnel Administration.

The following persons will serve on the Performance Review Boards or Panels which oversee the evaluation of performance appraisals of Senior Executive Service members of the Department of Health and Human Services:

William D. Adams
Michele Applegate
Bernard Arons
Thomas A. Ault
Wendy Baldwin, Ph.D.
Lyle W. Bivens, Ph.D.
Clarence J. Boone
Claire V. Broome, M.D.
Fernando Burbano
George Buzzard
Ronald H. Carlson
Ron Chesemore
Naomi Churchill
Elizabeth Cusick
Patricia Dalton
Diann Dawson
Gale A. Drapala
Florence B. Fiori, Dr. Ph.H.
Helene G. Gayle, M.D., M.P.H.
Ronald G. Geller, Ph.D.
Eric P. Goosby, M.D.
Michael M. Gottesman, M.D.
Richard J. Greene, M.D., Ph.D.
Robert Harris
Robert H. Harry, D.D.S.
Ileana Herrell
Richard J. Hodes, M.D.
Sharon Smith Holston
James M. Hughes, M.D.
Arthur C. Jackson
Richard J. Jackson
Walter L. Jackson
Thomas M. Kickham
Ruth L. Kirschstein
Claude Lenfant, M.D.
Arthur S. Levine, M.D.
Michel E. Lincoln
Merle G. McPherson, M.D.
John D. Mahoney
Michael Mangano
James S. Marks, M.D., M.P.H.
Naomi B. Marr
Steven A. Pelovitz
Vivian W. Pinn, M.D.
Louise Ramm, Ph.D.
Luana Reyes
Sally K. Richardson
William A. Robinson, M.D.
Linda Rosenstock, M.D., M.P.H.
Laura S. Rosenthal
Linda A. Ruiz
Marla E. Salmon, Sc.D.
Ruth D. Sanchez-Way, Ph.D.
Paul M. Schwab
William Shultz
Clay E. Simpson, Ph.D.
Allen M. Spiegel, M.D.
Robert O. Valdez
Judith N. Wasserheit, M.D.
Michael Zimmerman

[FR Doc. 95–25412 Filed 10–13–95; 8:45 am]

BILLING CODE 4150–04–M

Agency for Toxic Substances and Disease Registry

[ATSDR–100]

Availability of Final Toxicological Profiles

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Public Health Service (PHS), Department of Health and Human Services (HHS).

ACTION: Notice of availability.

SUMMARY: This notice announces the availability of 10 final toxicological profiles on unregulated hazardous substances prepared by ATSDR for the Department of Defense.

FOR FURTHER INFORMATION CONTACT: Ms. Kim E. Jenkins, Agency for Toxic Substances and Disease Registry, Division of Toxicology, 1600 Clifton Road, NE., Mailstop E–29, Atlanta, Georgia 30333, telephone (404) 639–6357.

SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99–499) amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (Superfund) or CERCLA. Section 211 of SARA also amended Title 10 of the U.S. Code, creating the Defense Environmental Restoration Program. Section 2704(a) of Title 10 of the U.S. Code directs the Secretary of Defense to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found, unregulated hazardous substances at defense facilities. Each profile or technical report includes an examination, summary and interpretation of available toxicological information and epidemiological evaluations. This information and these data are used to ascertain the levels of significant human exposure for the substance and the associated health effects. The profiles or technical reports include a determination of whether adequate information on the health effects of each substance is available or under development. When adequate information is not available, in cooperation with the National Toxicology Program (NTP), ATSDR may plan a program of research designed to determine these health effects.

Notice of the availability of 10 new draft toxicological profiles and 1 technical report for public review and comment was published in the Federal Register on September 1, 1993, (58 FR 46196), with notice of a 90-day public comment period for each profile, starting from the actual release date. Following the close of each comment period, chemical-specific comments were addressed, and where appropriate, changes were incorporated into each profile.

The public comments, the classification of and response to those comments, and other data submitted in response to the Federal Register notice bear the docket control number ATSDR–71. This material is available for public inspection at the Division of Toxicology, Agency for Toxic Substances and Disease Registry, Building 4, Suite 2400, Executive Park Drive, Atlanta, Georgia

(not a mailing address), between 8 a.m. and 4:30 p.m., Monday through Friday, except legal holidays.

Availability

This notice announces the availability of the first 10 final toxicological profiles for the Department of Defense. The draft technical report previously released for public comment has been developed into a toxicological profile that will be released with the next set of profiles for the Department of Defense. The following toxicological profiles are now available through the U.S. Department of Commerce, National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, telephone 1–800–553–6847. There is a charge for these profiles as determined by NTIS.

Toxicological profile	NTIS order No.	CAS No.
1. Automotive Gasoline	PB95–264206	8006–61–9.
2. Diethyl Phthalate	PB95–264214	84–66–2.
3. Fuel Oils	PB95–264222	
Fuel Oil No. 1 (Kerosene)	.....	8008–20–6.
Fuel Oil No. 1-D (Diesel Fuel No. 1)	.....	No CAS #.
Fuel Oil No. 2 (Gas Oil)	.....	68476–30–2.
Fuel Oil No. 2-D (Diesel Fuel No. 2)	.....	68476–34–6.
Fuel Oil No. 4 (Residual Fuel)	.....	68476–31–3.
Fuel Oil UNSP	.....	No CAS #.
4. Jet Fuels JP–4	PB95–264230	50815–00–4.
Jet Fuels JP–7	No CAS #.	
5. Otto Fuel II and Its Components	PB95–264248	106602–80–6.
Propylene Glycol Dinitrate	.....	6423–43–4.
2-Nitrodiphenylamine	.....	119–75–5.
Dibutyl Sebacate	.....	109–43–3.
6. RDX	PB95–264255	121–82–4.
7. Stoddard Solvent	PB95–264263	8052–41–3.
8. Tetryl	PB95–264271	479–45–8.
9. 1,3-Dinitrobenzene	PB95–264289	99–65–0.
1,3,5-Trinitrobenzene	.....	99–35–4.
10. 2,4,6-Trinitrotoluene	PB95–264297	118–96–7.

Dated: October 10, 1995.

Claire V. Broome,

Deputy Administrator, Agency for Toxic Substances and Disease Registry.

[FR Doc. 95–25572 Filed 10–13–95; 8:45 am]

BILLING CODE 4163–70–P

Food and Drug Administration

[Docket No. 95N–0253J]

Analysis Regarding the Food and Drug Administration's Jurisdiction Over Nicotine-Containing Cigarettes and Smokeless Tobacco Products; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending to January 2, 1996, the comment period for the notice that appeared in the Federal Register of August 11, 1995 (60 FR 41453). The document contained FDA's factual and legal analysis regarding nicotine in cigarettes and smokeless tobacco products and whether the products are drug delivery devices within the meaning of the Federal Food, Drug, and Cosmetic Act (the act). As a result of this extension, the agency is providing a comment period of more than 140 days on the notice, and a comment period of more than 90 days from the date that additional documents that the agency considered were placed on display.

DATES: Comments by January 2, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Philip L. Chao, Office of Policy (HF–23), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3380.

SUPPLEMENTARY INFORMATION: In the Federal Register of August 11, 1995 (60 FR 41453), FDA issued a notice describing the results of FDA's extensive investigation of cigarettes and smokeless tobacco products. The notice contained a comprehensive analysis and detailed documentation regarding the agency's jurisdiction over such products. The results of the investigation and analysis supported a finding, at that time, that nicotine in cigarettes and smokeless tobacco products is a drug, and that these products are drug delivery devices within the meaning of the act. In issuing the notice, FDA also recognized the unique importance of the jurisdictional issue as well as the factual justification for any proposed rule concerning cigarettes and smokeless tobacco products and invited comment.

On August 16, 1995, all documents referred to in the notice were placed on public display at the Dockets Management Branch, except for a small number of documents identified as confidential and articles for which publicly available journal citations were given in the notice. The notice and the documents cited by the agency in support of the notice (except for those documents that the agency identified as confidential) have been publicly available since August 16, 1995. On September 29, 1995, FDA placed additional documents that the agency considered on public display at the Dockets Management Branch. Accordingly, FDA is extending the comment period to January 2, 1996. A deadline of December 28, 1995, would provide a comment period of 90 days from the date on which the agency placed additional documents that the agency considered on public display. Because December 28, 1995, is a Thursday and January 1, 1996, is a holiday, the agency does not anticipate that it will be able to undertake significant work on the comments until January 2, 1996. Therefore, the agency is extending the comment period until January 2, 1996.

Because of the public health importance of this matter, the agency advises that it does not anticipate granting further extensions of the comment period beyond January 2,